Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log
 | This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record. |
May 11, 2024 edit
Renamed edit
- Draft:Monepantel renamed to Monepantel.
Reassessed edit
- 1,6-Hexanediol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- 2-Fluoromethamphetamine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- 4-Bromofentanyl (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Acetarsol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Actaea racemosa (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Caffeine use for sport (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Dextrin (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Discovery and development of cephalosporins (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Mavorixafor (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Medicinal plants (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
- Naringenin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Nitroxoline (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- PH-responsive tumor-targeted drug delivery (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Category:Powders (talk) reassessed. Importance rating changed from Mid-Class to NA-Class. (rev · t)
- Seeding trial (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Selective norepinephrine reuptake inhibitor (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
- Toxicodynamics (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
Assessed edit
May 10, 2024 edit
Renamed edit
- EPI-7386 renamed to Masofaniten.
Assessed edit
- Chengdu Kanghong Pharmaceutical Group (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
- Draft:Felix Effah (talk) assessed. Importance assessed as NA-Class. (rev · t)
- Fluvoxamine (talk) assessed. Quality assessed as B-Class. (rev · t) Importance assessed as High-Class. (rev · t)
- Draft:Klick (talk) assessed. Importance assessed as NA-Class. (rev · t)
- Masofaniten (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Perhexiline (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
May 9, 2024 edit
Reassessed edit
- Clometerone (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Assessed edit
- Sinopharm (company) (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as High-Class. (rev · t)
Removed edit
- Draft:DHDK (talk) removed.
May 8, 2024 edit
Renamed edit
- Guaiacolsulfonate renamed to Guaiacolsulfonic acid.
- Rafutrombopag renamed to Hetrombopag.
- Tricaprin renamed to Tricaprin.
Reassessed edit
- Central Drugs Standard Control Organisation (talk) reassessed. Importance rating changed from Low-Class to High-Class. (rev · t)
- Diminazene (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fluralaner (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fluvalinate (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fomivirsen (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- GW0742 (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Hydralazine (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
- Indatuximab ravtansine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Lipoglycopeptide (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Lobucavir (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Lotilaner (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Nesiritide (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Olorinab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Riamilovir (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Assessed edit
- 1DD-LSD (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Alalevonadifloxacin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Drugs Controller General of India (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as High-Class. (rev · t)
- Guaiacolsulfonic acid (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
- Hetrombopag (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Levonadifloxacin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Olesoxime (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Physiologically based pharmacokinetic modelling (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
- Quantitative pharmacology (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
Removed edit
- Draft:ACME Research Solutions (talk) removed.
- Fluvoxamine (talk) removed.
- Draft:Green Veterinary Pharmacology (talk) removed.
- Perhexiline (talk) removed.